Obagi Medical Products And Suneva Medical Partner To Offer ReGenica® Facial Rejuvenation Complex

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin-health systems, and Suneva Medical, Inc., a rapidly growing aesthetics company, jointly announce a partnership to co-distribute ReGenica Facial Rejuvenation Complex.

This technologically advanced product supports a more rapid improvement in the appearance of post-laser skin by fusing the promise of stem cells with the power of growth factors. It has been clinically proven to accelerate the return of healthy appearing skin after a combination ablative/nonablative laser treatment compared to a vehicle control in two separate studies published in peer-reviewed journals ^1,2. Obagi is extremely pleased to be co-distributing the ReGenica Facial Rejuvenation Complex, along with the Suneva sales force. It can now offer a clinically proven post-procedure solution to its physicians and their patients.

ReGenica's secret lies in its Multipotent CCM Complex (Cell Conditioned Media) developed by Dr. Gail K. Naughton, a renowned pioneer in the field of regenerative medicine. CCM is a highly potent composition of active growth factors and proteins not found in any other skincare product and developed through a revolutionary and highly proprietary scientific method. Only ReGenica contains this breakthrough, bovine serum-free, multipotent CCM in an innovative formulation optimized with the most advanced cosmeceutical skin conditioning agents.

“Obagi is delighted to offer another revolutionary skincare solution to patients. The addition of the ReGenica line solidifies already existing evidence that Obagi is dedicated to delivering the most efficacious, innovative products to patients seeking real solutions,” Al Hummel, Obagi’s President and CEO, said. “The Facial Rejuvenation Complex addresses the need for post-procedure skincare treatments that are not only gentle and safe for compromised skin, but also accelerate the visible improvement in the appearance of side effects associated with procedures.”

“Obagi has significant expertise and a proven track record of marketing physician-dispensed products. We believe this relationship will accelerate our penetration in the marketplace and bring ReGenica Facial Rejuvenation Complex to more physicians in need of a cutting edge post-procedure solution and are excited to have a company as successful as Obagi as our partner,” commented Nicholas Teti, Chairman and Chief Executive Officer of Suneva Medical.

1 2 Next › Last »